14 results about "Tissue plasminogen activator" patented technology

The present invention provides methods for modifying a donor organ, e.g., liver, or a portion thereof. The methods comprise contacting the donor liver with lipid nanoparticles comprising RNA. Compositions of lipid nanoparticles comprising RNA are also provided. The disclosed LNPs may comprise an siRNA, e.g., targeting tissue plasminogen activator (tPA) or plasminogen activator inhibitor 1 (PAI-1). The LNPs may comprise an mRNA encoding a protein, e.g., Nuclear Factor-erythroid factor 2-related factor 2 (NRF2) or thrombomodulin.

This invention relates to the field of biological detection, and more particularly to the preparation method and application of the t-PAI·C detection kit. The invention provides a detection reagent comprising: antibody-coated magnetic microparticles and enzyme-labeled antibodies; the antibodies include: tissue plasminogen activator-plasminogen activator inhibitor-1 complex antibody. In the detection reagent provided by this invention, when the sample contains the tissue plasminogen activator-plasminogen activator inhibitor-1 complex, the antibody coated with the magnetic microparticles and the enzyme-labeled antibody undergo an immune reaction with the complex, forming a sandwich-like immune complex consisting of the antibody coated with the magnetic microparticles, the complex, and the enzyme-labeled antibody; the enzyme on this complex acts on a luminescent substrate and emits light, and the concentration of the complex in the sample is calculated by detecting the luminescence signal.

The invention relates to an antithrombotic catheter. The antithrombotic catheter comprises a hydrogel coating containing a thrombolytic agent. The thrombolytic agent may be a lyophilized tissue plasminogen activator. The catheter has an inner lumen surface and an outer lumen surface, and a hydrogel coating is disposed on the inner lumen surface and / or the outer lumen surface. The hydrogel coating may have a thickness in the range of about 50 nm to about 150 nm. The hydrogel coating may contain from about 0.1 wt% to about 1 wt% of a tissue plasminogen activator. The hydrogel coating may be made from a synthetic hydrogel or a natural hydrogel. Presently preferred synthetic hydrogels include polyacrylamide based hydrogels. Presently preferred natural hydrogels include hyaluronic acid based hydrogels. The hydrogel coating reacts in the presence of a physiological liquid to absorb water and elute the solvating suppository. The hydrogel controls elution of the thrombolytic agent. Examples of physiological fluids include interstitial fluids and blood.

Provided herein are methods for safe and effective thrombolysis in therapy for human subjects with symptoms of a potential stroke or acute myocardial infarction (“AMI”) using a sequential administration of a low dose bolus of human tissue plasminogen activator (“tPA”) followed by an infusion of a mutant form of human pro-urokinase (“proUK”).

Provided is a pharmaceutical composition with which it is possible to prevent the development of late-onset cerebral ischemia and obtain a prognosis-improving effect by performing active hematoma removal using a tissue plasminogen activator. This pharmaceutical composition contains a tissue plasminogen activator as an active ingredient and is for use in hematoma removal therapy in the cerebral cistern to remove a dislodged hematoma by suction by using the tissue plasminogen activator in an aqueous solution state as a cleansing agent, said therapy being performed at the same time as treatment of a cerebral aneurysm by means of craniotomy with clipping during the acute phase of a subarachnoid hemorrhage associated with a ruptured cerebral aneurysm.

This invention discloses a sonodynamic synergistic thrombolysis system and its application. The system includes a tissue plasminogen activator variant, a sonosensitive agent, and an ultrasound source. The tissue plasminogen activator variant is an intravenously administered formulation, the sonosensitive agent is an intravenously infused formulation, and the ultrasound source is used to emit ultrasound during sonosensitive agent administration to activate the agent. This invention significantly improves thrombolysis efficiency and reduces thrombolytic agent dosage and bleeding risk through the dual synergistic effect of TNK-tPA enzymatic hydrolysis and sonodynamic chemical oxidation. The system can significantly improve vascular recanalization rate and blood flow velocity recovery rate, and has high biocompatibility. This invention is applicable to thrombolytic treatment of various thrombotic diseases and has the advantages of simple operation, strong targeting, and wide application range.

The present invention provides tissue plasminogen activator antibody molecules and their uses. More particularly, the presently-disclosed invention provides humanised antibody molecules which specifically bind tissue plasminogen activator (TPA) and their use in treating TPA induced haemorrhage, in particular treating systemic haemorrhage such as brain haemorrhage after treatment of ischemic stroke or myocardial infarction, or systemic bleeding after TPA treatment of pulmonary embolism, ischemic stroke or myocardial infarction.

The present invention relates to novel affinity ligands that bind to human tissue plasminogen activator (tPA). The novel affinity ligands of the present invention are powerful tools because they allow efficient purification methods for human tPA via affinity chromatography. In particular, the affinity ligands are powerful in the purification of recombinant human tPA that was produced in Chinese hamster ovary cells because the affinity ligands of the invention do not detectably bind to hamster tPA. Accordingly, the present invention also relates to a novel process of isolating and purifying tPA, specifically tPA from CHO cells.

A fusion protein is provided. [Solution] The fusion protein of the present invention comprises a tissue plasminogen activator or a variant thereof, a disintegrin or a variant thereof, and a connector that binds the tissue plasminogen activator or a variant thereof and the disintegrin or variant thereof and comprises an amino acid sequence set forth in any one of SEQ ID NOs: 1 to 7. The present invention further provides a method for using the fusion protein in the treatment or prevention of a disease associated with thrombus formation.

The application provides application of capillary electrophoresis-mass spectrometry online connection, a detection method of tissue plasminogen activator drug heteromer, and relates to the technical field of analysis and detection.The application utilizes online capillary electrophoresis and mass spectrometry connection, separates t-PA through a capillary zone electrophoresis (CZE) mode, uses a neutral coating capillary, uses an acid-water mixed solution or an acid-acetonitrile-water mixed solution as an electrophoresis background buffer, adopts air pressure sampling, applies a separation voltage to perform capillary zone electrophoresis, effectively separates the heteromer in the t-PA drug through CZE, then introduces a mass spectrometer through an electric osmosis flow driven coaxial sheath flow liquid electrospray ion source for detection and analysis, realizes high-efficiency, accurate and high-sensitivity detection of the heteromer in the t-PA drug.Further, the capillary electrophoresis-mass spectrometry online connection detection adopted by the application is short in time consumption, small in required sample amount, and provides a reliable means for evaluating the quality and stability of the t-PA drug.

The inventors have now succeeded in efficiently conjugating clusters of ultrasmall particles of iron oxide (USPIO) and polycathecolamine or polyserotonine with an activator of fibrinolysis, in particular a tissue plasminogen activator (tPA). Such conjugates are useful for detecting microthrombi in a condition requiring thrombolysis, in particular acute ischemic stroke, by magnetic resonance imaging (MRI), and for treating a condition requiring thrombolysis, in particular acute ischemic stroke. The present invention relates to conjugate comprising a suspension of biocompatible particles comprising ultrasmall particles of iron oxide embedded in a polycathecolamine or polyserotonine matrix, an activator of fibrinolysis or a fragment thereof and optionally a deoxyribonuclease, and its use in an in vivo method of detection of microthrombi in a condition requiring thrombolysis, in particular acute ischemic stroke, by magnetic resonance imaging (MRI) and in the treatment of a condition requiring thrombolysis, in particular ischemic stroke.

The present invention provides tissue plasminogen activator antibody molecules and their uses. More particularly, the presently-disclosed invention provides humanised antibody molecules which specifically bind tissue plasminogen activator (TPA) and their use in treating TPA induced haemorrhage, in particular treating systemic haemorrhage such as brain haemorrhage after treatment of ischemic stroke or myocardial infarction, or systemic bleeding after TPA treatment of pulmonary embolism, ischemic stroke or myocardial infarction.

The present technology relates to recombinant polypeptides, or nucleotides encoding the same, comprising tissue plasminogen activator (tPA) fragments and uses thereof for treating cardiovascular diseases. In some embodiments, the tPA fragments comprise the kringle 2 domain of tPA.

This article provides truncated tissue plasminogen activator (tPA) variants and vectors encoding tPA variants (e.g., AAV vectors). Pharmaceutical compositions comprising tPA variants and vectors are also provided, along with therapeutic uses of the pharmaceutical compositions for treating intraocular pressure (IOP)-related conditions such as glaucoma.